Early Results Look Good for Johnson & Johnson Vacc
Post# of 716
(Total Views: 533)
Posted On: 10/01/2020 3:03:55 PM
Early Results Look Good for Johnson & Johnson Vaccine Ad26.COV2.S COVID-19
SEP 30, 2020 | AD26.COV2-S, COVID-19, JOHNSON & JOHNSON, NEWS, VACCINE
Early results from Johnson & Johnson’s COVID-19 vaccine (Ad26.COV2.S COVID-19) were published in the preprint server medRxiv last week and although not peer-reviewed as of yet, they do suggest that a single dose of the J&J vaccine safely elicits antibody responses across most demographic cohorts. Led by Dan H Barouch, Harvard Medical School alumni and Director of Beth Israel Center for Virology and Vaccine Research, the study is based on J&J’s deactivated common cold virus for the viral vector for delivery of the vaccine’s spike protein to host cells for the immune response sought after, reports Alex M. Alex M. Koller of the Harvard Crimson.
The Study Results Thus Far
With the recent early results in, this promising vaccine gains even more attention due to the “single shot” feature, making it far easier to take and administer in the real world. Additionally, the vaccine’s stability isn’t conditioned on a freezing temperature and can remain stable at standard refrigerated temperatures for up to three months, writes Koller with the Harvard Crimson.
Furthermore, as TrialSite has suggested Johnson & Johnson, one of the world’s largest pharmaceutical companies, can’t be underestimated as a leading contender for the next “2.0” batch of COVID-19 vaccines.
Still Early but the Phase 3 Trial Commences
Nonetheless, there’s a long way to go for Ad26.COV2.S COVID-19. Although TrialSite has suggested that the pharma giant has picked up speed, but a giant 60,000 participant study (NCT04505722) will ultimately yield more actionable data.
Lead Research/Investigator at Harvard
Dan H Barouch, MD, PhD, Harvard Medical School alumni and Director of Beth Israel Center for Virology and Vaccine Research
SEP 30, 2020 | AD26.COV2-S, COVID-19, JOHNSON & JOHNSON, NEWS, VACCINE
Early results from Johnson & Johnson’s COVID-19 vaccine (Ad26.COV2.S COVID-19) were published in the preprint server medRxiv last week and although not peer-reviewed as of yet, they do suggest that a single dose of the J&J vaccine safely elicits antibody responses across most demographic cohorts. Led by Dan H Barouch, Harvard Medical School alumni and Director of Beth Israel Center for Virology and Vaccine Research, the study is based on J&J’s deactivated common cold virus for the viral vector for delivery of the vaccine’s spike protein to host cells for the immune response sought after, reports Alex M. Alex M. Koller of the Harvard Crimson.
The Study Results Thus Far
With the recent early results in, this promising vaccine gains even more attention due to the “single shot” feature, making it far easier to take and administer in the real world. Additionally, the vaccine’s stability isn’t conditioned on a freezing temperature and can remain stable at standard refrigerated temperatures for up to three months, writes Koller with the Harvard Crimson.
Furthermore, as TrialSite has suggested Johnson & Johnson, one of the world’s largest pharmaceutical companies, can’t be underestimated as a leading contender for the next “2.0” batch of COVID-19 vaccines.
Still Early but the Phase 3 Trial Commences
Nonetheless, there’s a long way to go for Ad26.COV2.S COVID-19. Although TrialSite has suggested that the pharma giant has picked up speed, but a giant 60,000 participant study (NCT04505722) will ultimately yield more actionable data.
Lead Research/Investigator at Harvard
Dan H Barouch, MD, PhD, Harvard Medical School alumni and Director of Beth Israel Center for Virology and Vaccine Research
(0)
(0)